Emend
aprepitant
Keep this leaflet. You may need to read it again.
If you have any further questions, ask the doctor, pharmacist, or nurse.
This medicine has been prescribed for you or the child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same.
If you or the child gets any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
What EMEND is and what it is used for
What you need to know before you take or give EMEND
How to take EMEND
Possible side effects
How to store EMEND
Contents of the pack and other information
EMEND contains the active substance aprepitant and belongs to a group of medicines called "neurokinin 1 (NK1) receptor antagonists". The brain has a specific area that controls nausea and vomiting. EMEND works by blocking signals to that area, thereby reducing nausea and vomiting. EMEND capsules are used in adults and adolescents from the age of 12 years incombinationwith othermedicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment) that are strong and moderate triggers of nausea and vomiting (such as cisplatin, cyclophosphamide, doxorubicin or epirubicin).
if you or the child is allergic to aprepitant or any of the other ingredients of this medicine (listed in section 6).
with medicines containing pimozide (used to treat psychiatric illnesses), terfenadine and astemizole (used for hay fever and other allergic conditions), cisapride (used for treating digestive problems). Tell the doctor if you or the child is taking these medicines since the treatment must be modified before you or the child start taking EMEND.
Talk to the doctor, pharmacist, or nurse before you take EMEND or give this medicine to the child.
Before treatment with EMEND, tell the doctor if you or the child have liver disease because the liver is important in breaking down the medicine in the body. The doctor may therefore have to monitor the
condition of your or the child’s liver.
Do not give EMEND 80 mg and 125 mg capsules to children under 12 years of age, because the 80 mg and 125 mg capsules have not been studied in this population.
EMEND can affect other medicines both during and after treatment with EMEND. There are some medicines that should not be taken with EMEND (such as pimozide, terfenadine, astemizole, and
cisapride) or that require a dose adjustment (see also ‘Do not take EMEND’).
The effects of EMEND or other medicines might be influenced if you or the child take EMEND together with other medicines including those listed below. Please talk to the doctor or pharmacist if you or the child is taking any of the following medicines:
birth control medicines which can include birth control pills, skin patches, implants, and certain Intrauterine devices (IUDs) that release hormones may not work adequately when taken together with EMEND. Another or additional non-hormonal form of birth control should be used during treatment with EMEND and for up to 2 months after using EMEND,
- cyclosporine, tacrolimus, sirolimus, everolimus (immunosuppressants),
alfentanil, fentanyl (used to treat pain),
quinidine (used to treat an irregular heart beat),
irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer),
medicines containing ergot alkaloid derivatives such as ergotamine and diergotamine (used for treating migraines),
warfarin, acenocoumarol (blood thinners; blood tests may be required),
rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections),
phenytoin (a medicine used to treat seizures),
carbamazepine (used to treat depression and epilepsy),
midazolam, triazolam, phenobarbital (medicines used to produce calmness or help you sleep),
St. John’s Wort (an herbal preparation used to treat depression),
protease inhibitors (used to treat HIV infections),
ketoconazole except shampoo (used to treat Cushing’s syndrome - when the body produces an excess of cortisol),
itraconazole, voriconazole, posaconazole (antifungals),
nefazodone (used to treat depression),
corticosteroids (such as dexamethasone and methylprednisolone),
anti-anxiety medicines (such as alprazolam),
tolbutamide (a medicine used to treat diabetes).
Tell the doctor or pharmacist if you or the child are taking, have recently taken, or might take any other medicines.
This medicine should not be used during pregnancy unless clearly necessary. If you or the child are pregnant or breast-feeding, may be pregnant or are planning to have a baby, ask the doctor for advice before taking this medicine.
For information regarding birth control, see ‘Other medicines and EMEND’.
It is not known whether EMEND is excreted in human milk; therefore, breast-feeding is not recommended during treatment with this medicine. It is important to tell the doctor if you or the child are breast-feeding or are planning to breast-feed before taking this medicine.
It should be taken into account that some people feel dizzy and sleepy after taking EMEND. If you or the child feels dizzy or sleepy, avoid driving, riding a bicycle or using machines or tools after taking
this medicine (see ‘Possible side effects’).
EMEND capsules contain sucrose. If you or the child have been told by your doctor that you or the child have an intolerance to some sugars, contact the doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially
‘sodium-free’.
Always take this medicine or give this medicine to the child exactly as the doctor, pharmacist or nurse has told you. You should check with the doctor, pharmacist or nurse if you are not sure. Always take EMEND together with other medicines, to prevent nausea and vomiting. After treatment with EMEND, the doctor may ask you or the child to continue taking other medicines including a
corticosteroid (such as dexamethasone) and a ‘5HT3 antagonist’ (such as ondansetron) for preventing
nausea and vomiting. Check with the doctor, pharmacist or nurse if you are not sure.
The recommended oral dose of EMEND is: Day 1:
one 125 mg capsule 1 hour before you start your chemotherapy session
Days 2 and 3:
one 80 mg capsule each day
If no chemotherapy is given, take EMEND in the morning.
If chemotherapy is given, take EMEND 1 hour before you start your chemotherapy session. EMEND can be taken with or without food.
Swallow the capsule whole with some liquid.
Do not take more capsules than the doctor recommends. If you or the child has taken too many capsules, contact your doctor immediately.
If you or the child has missed a dose, contact your doctor for advice.
If you have any further questions on the use of this medicine, ask the doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Hives, rash, itching, difficulty breathing or swallowing (frequency not known, cannot be
estimated from the available data); these are signs of an allergic reaction. Other side effects that have been reported are listed below.
constipation, indigestion,
headache,
tiredness,
loss of appetite,
hiccups,
increased amount of liver enzymes in your blood.
dizziness, sleepiness,
acne, rash,
anxiousness,
burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind,
increased painful or burning urination,
weakness, generally feeling unwell,
hot flush/reddening of the face or skin,
fast or irregular heartbeats,
fever with increased risk of infection, lowering of red blood cells.
difficulty thinking, lack of energy, taste disturbance,
sensitivity of the skin to sun, excessive sweating, oily skin, sores on skin, itching rash, Stevens-Johnson syndrome/toxic epidermal necrolysis (rare severe skin reaction),
euphoria (feeling of extreme happiness), disorientation,
bacterial infection, fungal infection,
severe constipation, stomach ulcer, inflammation of the small intestine and colon, sores in mouth, bloating,
frequent urination, passing more urine than normal, presence of sugar or blood in urine,
chest discomfort, swelling, change in the manner of walking,
cough, mucus in back of throat, throat irritation, sneezing, sore throat,
eye discharge and itching,
ringing in the ear,
muscle spasms, muscle weakness,
excessive thirst,
slow heartbeat, heart and blood vessel disease,
lowering of white blood cells, low sodium levels in the blood, weight loss.
If you or the child gets any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
Store in the original package in order to protect from moisture.
Do not remove the capsule from its blister until you are ready to take it.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is aprepitant. Each 125 mg hard capsule contains 125 mg of aprepitant.
Each 80 mg hard capsule contains 80 mg of aprepitant.
The other ingredients are sucrose, microcrystalline cellulose (E 460), hydroxypropylcellulose (E 463), sodium laurilsulfate, gelatin, titanium dioxide (E 171), shellac, potassium hydroxide, and black iron oxide (E 172); the 125 mg hard capsule also contains red iron oxide (E 172) and yellow iron oxide (E 172).
The 125 mg hard capsule is opaque with a white body and pink cap with “462” and “125 mg” printed
radially in black ink on the body.
The 80 mg hard capsule is opaque with a white cap and body with “461” and “80 mg” printed radially
in black ink on the body.
EMEND 125 mg and 80 mg hard capsules are supplied in the following pack sizes:
Aluminium blister containing one 80 mg capsule
2-day treatment pack containing two 80 mg capsules
5 Aluminium blisters each containing one 80 mg capsule
Aluminium blister containing one 125 mg capsule
5 Aluminium blisters each containing one 125 mg capsule
3-day treatment pack containing one 125 mg capsule and two 80 mg capsules Not all pack sizes may be marketed.
Merck Sharp & Dohme B.V. Waarderweg 39
2031 BN Haarlem The Netherlands
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
MSD Belgium
Tél/Tel: +32(0)27766211
UAB Merck Sharp & Dohme Tel. + 370 5278 02 47
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
MSD Belgium
Tél/Tel: +32(0)27766211
Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111
MSD Pharma Hungary Kft. Tel.: +36 1 888 5300
MSD Danmark ApS Tlf: + 45 4482 4000
Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558)
MSD Sharp & Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
Merck Sharp & Dohme B.V.
Tel: 0800 9999000
(+31 23 5153153)
Merck Sharp & Dohme OÜ Tel.: +372 6144 200
MSD (Norge) AS Tlf: +47 32 20 73 00
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
Merck Sharp & Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00
MSD Polska Sp. z o.o. Tel: +48 22 549 51 00
MSD France
Tél: +33 (0) 1 80 46 40 40
Merck Sharp & Dohme, Lda Tel: +351 21 4465700
Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333
Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00
Merck Sharp & Dohme Ireland (Human Health) Limited
Tel: +353 (0)1 2998700
Merck Sharp & Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 201
Vistor hf.
Simi: +354 535 7000
Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010
MSD Italia S.r.l.
Tel: +39 06 361911
medicalinformation.it@merck.com
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
Merck Sharp & Dohme Cyprus Limited
Τηλ.: 800 00 673 (+357 22866700)
Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224
Tel: +353 (0)1 2998700